JP2011516840A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011516840A5 JP2011516840A5 JP2011502199A JP2011502199A JP2011516840A5 JP 2011516840 A5 JP2011516840 A5 JP 2011516840A5 JP 2011502199 A JP2011502199 A JP 2011502199A JP 2011502199 A JP2011502199 A JP 2011502199A JP 2011516840 A5 JP2011516840 A5 JP 2011516840A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- soluble
- level
- biological fluid
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 81
- 239000013060 biological fluid Substances 0.000 claims description 25
- 102100021396 Cell surface glycoprotein CD200 receptor 1 Human genes 0.000 claims description 8
- 101000969553 Homo sapiens Cell surface glycoprotein CD200 receptor 1 Proteins 0.000 claims description 8
- 210000004027 cell Anatomy 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 238000003556 assay Methods 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 7
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 230000001413 cellular effect Effects 0.000 claims description 4
- 238000003745 diagnosis Methods 0.000 claims description 4
- 230000037361 pathway Effects 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- 206010066476 Haematological malignancy Diseases 0.000 claims description 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 2
- 101100135226 Homo sapiens CD200 gene Proteins 0.000 claims description 2
- 238000004820 blood count Methods 0.000 claims description 2
- 210000000265 leukocyte Anatomy 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 230000002018 overexpression Effects 0.000 claims description 2
- 238000010837 poor prognosis Methods 0.000 claims description 2
- 238000004393 prognosis Methods 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 230000011664 signaling Effects 0.000 claims 2
- 238000000968 medical method and process Methods 0.000 claims 1
- 238000002965 ELISA Methods 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 238000003118 sandwich ELISA Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010020631 Hypergammaglobulinaemia benign monoclonal Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000004346 Smoldering Multiple Myeloma Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 208000006178 malignant mesothelioma Diseases 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 201000005328 monoclonal gammopathy of uncertain significance Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 201000009295 smoldering myeloma Diseases 0.000 description 1
- 208000010721 smoldering plasma cell myeloma Diseases 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 208000008732 thymoma Diseases 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4234208P | 2008-04-04 | 2008-04-04 | |
| US61/042,342 | 2008-04-04 | ||
| PCT/CA2008/001385 WO2009121162A1 (en) | 2008-04-04 | 2008-07-29 | Assay for soluble cd200 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011516840A JP2011516840A (ja) | 2011-05-26 |
| JP2011516840A5 true JP2011516840A5 (enExample) | 2011-09-15 |
Family
ID=41134766
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011502199A Pending JP2011516840A (ja) | 2008-04-04 | 2008-07-29 | 可溶性ｃｄ２００に関するアッセイ法 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US8206897B2 (enExample) |
| JP (1) | JP2011516840A (enExample) |
| CA (1) | CA2720294A1 (enExample) |
| WO (1) | WO2009121162A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019084682A1 (en) * | 2017-10-30 | 2019-05-09 | Mcmaster University | Methods for the diagnosis and treatment of endometriosis |
| US20220396619A1 (en) * | 2019-11-12 | 2022-12-15 | Eli Lilly And Company | Cd200 receptor antagonist binding molecules |
| CN116323665A (zh) * | 2020-05-29 | 2023-06-23 | 23和我公司 | 抗cd200r1抗体及其使用方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5401638A (en) * | 1986-06-04 | 1995-03-28 | Oncogene Science, Inc. | Detection and quantification of neu related proteins in the biological fluids of humans |
| EP1337560B8 (en) * | 2000-11-22 | 2008-10-15 | Trillium Therapeutics Inc. | Truncated cd200 |
| US20060057651A1 (en) * | 2000-12-08 | 2006-03-16 | Bowdish Katherine S | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
| CA2554628A1 (en) * | 2004-02-02 | 2005-08-18 | Schering Corporation | Methods of modulating cd200 and cd200r |
| KR20140091765A (ko) | 2006-01-12 | 2014-07-22 | 알렉시온 파마슈티칼스, 인코포레이티드 | Ｏｘ-2/ｃｄ200에 대한 항체 및 이들의 용도 |
| EP1880729A1 (en) * | 2006-07-20 | 2008-01-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of soluble CD160 to suppress immunity |
-
2008
- 2008-07-29 CA CA2720294A patent/CA2720294A1/en not_active Abandoned
- 2008-07-29 WO PCT/CA2008/001385 patent/WO2009121162A1/en not_active Ceased
- 2008-07-29 JP JP2011502199A patent/JP2011516840A/ja active Pending
- 2008-07-29 US US12/936,094 patent/US8206897B2/en not_active Expired - Fee Related
-
2012
- 2012-05-18 US US13/474,855 patent/US20120264145A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5714019B2 (ja) | 急性心不全の診断、予知及び／又は予後用バイオマーカー及びその使用 | |
| JP2007525427A5 (enExample) | ||
| CN104530234B (zh) | 检测人vegf的组合试剂、试剂盒及其使用方法 | |
| RU2009141523A (ru) | Биомаркеры для рассеянного склероза | |
| CA2522747A1 (en) | Method of detecting native probnp with a monoclonal antibody binding to the amino acids 38-43 | |
| WO2010038974A3 (ko) | 이뮤노글로블린 에이 신증과 티지비엠 신증의 진단용 조성물 및 키트 | |
| JP2015533788A5 (enExample) | ||
| JP2007535470A5 (enExample) | ||
| JP2012509477A5 (enExample) | ||
| JP2022122924A (ja) | 急性心不全に罹患している対象におけるうっ血を評価するためのアドレノメデュリン | |
| JP6840136B2 (ja) | 黒色腫の診断マーカーとしてのｇｄｆ−１５ | |
| JP2015514707A5 (enExample) | ||
| CN114573692B (zh) | 用于检测嗜铬粒蛋白a的免疫测定与抗体 | |
| CN103091496A (zh) | 免疫测定试剂、生物传感器和检测分析物的方法 | |
| US20180299399A1 (en) | Electrochemical assay for a protein analyte | |
| JP2011516840A5 (enExample) | ||
| JP2007518985A (ja) | ウロテンシンｉｉを測定することによって、急性冠状動脈症候群を診断する方法 | |
| WO2021097684A1 (zh) | 新的抗可溶性cd14亚型抗体及其应用 | |
| CN104781672B (zh) | 预测女性对象患癌症风险或诊断其癌症的方法 | |
| JP5961608B2 (ja) | ＥｐｈＡ４細胞外ドメインの測定による認知機能障害を伴う神経系疾患の検出方法 | |
| CN102753973A (zh) | Ku86和其自身抗体的复合物的免疫测定方法、其中使用的试剂盒及使用其的癌判断方法 | |
| WO2007089563A3 (en) | Rabbit monoclonal antibodies against mouse/human id3 proteins | |
| WO2021253335A1 (zh) | 抗可溶性cd14亚型抗体、试剂盒及其应用 | |
| WO2006013474A8 (en) | Ppgalnac-t6 mrna or peptide as a new marker for detection cancer cells | |
| JPH10504902A (ja) | 遊離及び複合化トリプシノーゲン−２のアッセイ |